Neurogene CFO sells 4,800 shares under 10b5-1 plan

Neurogene Inc. President and CFO Christine Mikail Cvijic reported open-market sales of 4,800 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Neurogene Inc. President and CFO Christine Mikail Cvijic reported open-market sales of 4,800 shares of common stock under a pre-arranged Rule 10b5-1 trading plan. The sales occurred on two days at weighted average prices around the mid-$36 range.

After these transactions, she reports ownership of 84,040 shares, which includes 10,635 restricted stock units scheduled to vest on March 13, 2027, 13,533 restricted stock units vesting in equal installments on March 26, 2027 and March 26, 2028, and 22,000 restricted stock units vesting annually from February 20, 2027 through February 20, 2029. The filing notes that following completion of these sales she no longer holds any shares jointly with her spouse.

Insider Trade Summary 10b5-1

Net Seller: 4,800 shares

Net Sell 2 txns

Insider Cvijic Christine Mikail

Role President and CFO

Sold 4,800 shs ($173K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,200	$36.134	$152K
Sale	Common Stock	600	$36.021	$22K

Holdings After Transaction: Common Stock — 84,040 shares (Direct)

Footnotes (4)

1. F1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse.
4. F4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold July 7, 2026: 4,200 shares Shares sold July 6, 2026: 600 shares Total shares sold: 4,800 shares +5 more

8 metrics

Shares sold July 7, 2026 4,200 shares Open-market sale of common stock at weighted average $36.134

Shares sold July 6, 2026 600 shares Open-market sale of common stock at weighted average $36.021

Total shares sold 4,800 shares Net open-market sales reported across both transactions

Shares owned after transactions 84,040 shares Total beneficial ownership reported following all sales on this Form 4

RSUs vesting March 13, 2027 10,635 RSUs Restricted stock units granted March 13, 2024 vesting on March 13, 2027

RSUs vesting March 26, 2027-2028 13,533 RSUs Restricted stock units vesting in equal installments on March 26, 2027 and March 26, 2028

RSUs vesting 2027-2029 22,000 RSUs Restricted stock units vesting annually on February 20, 2027, 2028 and 2029

10b5-1 plan adoption date August 18, 2025 Date reporting person adopted the trading plan governing these sales

Key Terms

Rule 10b5-1 plan, restricted stock units, weighted average price, open-market sale, +1 more

5 terms

Rule 10b5-1 plan regulatory

"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock units financial

"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: "open-market sale" with transaction code "S" for common stock on July 6 and July 7, 2026."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

beneficial ownership financial

"Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Neurogene (NGNE) report for Christine Mikail Cvijic?

Neurogene’s President and CFO, Christine Mikail Cvijic, reported selling a total of 4,800 shares of common stock in open-market transactions. The sales were executed over two days at weighted average prices in the mid-$36 range under a pre-arranged Rule 10b5-1 trading plan.

At what prices were the Neurogene (NGNE) insider sales by the CFO executed?

The reported insider sales were executed at weighted average prices of $36.134 and $36.021 per share. Footnotes explain these were composed of multiple trades in ranges from $36.00 up to $36.455 per share, with full breakdowns available upon request to the company or SEC staff.

How many Neurogene (NGNE) shares does the CFO hold after these insider sales?

Following the reported transactions, Christine Mikail Cvijic reports beneficial ownership of 84,040 shares of Neurogene common stock. This figure includes multiple tranches of restricted stock units that will vest between March 2027 and February 2029 according to the schedules described in the filing footnotes.

Were the Neurogene (NGNE) insider sales by the CFO under a Rule 10b5-1 plan?

Yes. The filing states that all transactions on this Form 4 were effected under a Rule 10b5-1 trading plan adopted on August 18, 2025. Such plans pre-schedule trades, indicating the timing of these sales was determined in advance rather than decided opportunistically.

What restricted stock units does the Neurogene (NGNE) CFO hold and when do they vest?

The CFO’s holdings include 10,635 restricted stock units vesting March 13, 2027; 13,533 units vesting in equal installments on March 26, 2027 and March 26, 2028; and 22,000 units vesting annually on February 20, 2027, February 20, 2028, and February 20, 2029, subject to applicable conditions.

Does the Neurogene (NGNE) CFO still hold shares jointly with her spouse after these sales?

According to a footnote, the shares sold in these transactions were held jointly with her spouse, David Cvijic. The filing further states that after completing all sales reported on this Form 4, she no longer holds any Neurogene shares jointly with her spouse.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 09:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cvijic Christine Mikail

(Last) (First) (Middle)

C/O NEUROGENE INC.

535 W 24TH STREET, 5TH FLOOR

(Street)

NEW YORK NEW YORK 10011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neurogene Inc. [ NGNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		S(1)		600	D	$36.021(2)	88,240	D(3)
Common Stock	07/07/2026		S(1)		4,200	D	$36.134(4)	84,040	D(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Donna M. Cochener as attorney-in-fact for Christine Mikail Cvijic	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)